Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1016/j.cell.2020.04.020 http://scihub22266oqcxt.onion/10.1016/j.cell.2020.04.020 32353252!7189862!32353252     free     free     free Warning: file_get_contents(https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=32353252&cmd=llinks): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 215 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Cell 2020 ; 181 (4): 865-876.e12 Nephropedia Template TP {{tp|p=32353252|t=2020. Development of CRISPR as an Antiviral Strategy to Combat SARS-CoV-2 and Influenza |pdf=|usr=}}{{32353252}} gab.com Text Development of CRISPR as an Antiviral Strategy to Combat SARS-CoV-2 and Influenza JO: Cell http://www.kidney.de/pget.php?&tw=1&pmid=32353252 #FOAvip The coronavirus disease 2019 (COVID-19) pandemic, caused by the SARS-CoV-2 virus, has highlighted the need for antiviral approaches that can target emerging viruses with no effective vaccines or pharmaceuticals. Here, we demonstrate a CRISPR-Cas13-based strategy, PAC-MAN (prophylactic antiviral CRISPR in human cells), for viral inhibition that can effectively degrade RNA from SARS-CoV-2 sequences and live influenza A virus (IAV) in human lung epithelial cells. We designed and screened CRISPR RNAs (crRNAs) targeting conserved viral regions and identified functional crRNAs targeting SARS-CoV-2. This approach effectively reduced H1N1 IAV load in respiratory epithelial cells. Our bioinformatic analysis showed that a group of only six crRNAs can target more than 90% of all coronaviruses. With the development of a safe and effective system for respiratory tract delivery, PAC-MAN has the potential to become an important pan-coronavirus inhibition strategy. Twit Text FOAVip Development of CRISPR as an Antiviral Strategy to Combat SARS-CoV-2 and Influenza ????Cell http://www.kidney.de/pget.php?&tw=1&pmid=32353252 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=32353252 #FOAvip English Wikipedia <ref>{{Cite pmid|32353252}}</ref> Development of CRISPR as an Antiviral Strategy to Combat SARS-CoV-2 and Influenza #MMPMID32353252 Abbott TR; Dhamdhere G; Liu Y; Lin X; Goudy L; Zeng L; Chemparathy A; Chmura S; Heaton NS; Debs R; Pande T; Endy D; La Russa MF; Lewis DB; Qi LS Cell 2020[May]; 181 (4): 865-876.e12 PMID32353252show ga The coronavirus disease 2019 (COVID-19) pandemic, caused by the SARS-CoV-2 virus, has highlighted the need for antiviral approaches that can target emerging viruses with no effective vaccines or pharmaceuticals. Here, we demonstrate a CRISPR-Cas13-based strategy, PAC-MAN (prophylactic antiviral CRISPR in human cells), for viral inhibition that can effectively degrade RNA from SARS-CoV-2 sequences and live influenza A virus (IAV) in human lung epithelial cells. We designed and screened CRISPR RNAs (crRNAs) targeting conserved viral regions and identified functional crRNAs targeting SARS-CoV-2. This approach effectively reduced H1N1 IAV load in respiratory epithelial cells. Our bioinformatic analysis showed that a group of only six crRNAs can target more than 90% of all coronaviruses. With the development of a safe and effective system for respiratory tract delivery, PAC-MAN has the potential to become an important pan-coronavirus inhibition strategy. |*CRISPR-Cas Systems[MESH] |A549 Cells[MESH] |Antibiotic Prophylaxis/methods[MESH] |Antiviral Agents/*pharmacology[MESH] |Base Sequence[MESH] |Betacoronavirus/*drug effects/genetics/growth & development[MESH] |COVID-19[MESH] |Clustered Regularly Interspaced Short Palindromic Repeats[MESH] |Computer Simulation[MESH] |Conserved Sequence[MESH] |Coronavirus Infections/drug therapy[MESH] |Coronavirus Nucleocapsid Proteins[MESH] |Coronavirus RNA-Dependent RNA Polymerase[MESH] |Coronavirus/drug effects/genetics/growth & development[MESH] |Epithelial Cells/virology[MESH] |Humans[MESH] |Influenza A Virus, H1N1 Subtype/*drug effects/genetics/growth & development[MESH] |Lung/pathology/virology[MESH] |Nucleocapsid Proteins/genetics[MESH] |Pandemics[MESH] |Phosphoproteins[MESH] |Phylogeny[MESH] |Pneumonia, Viral/drug therapy[MESH] |RNA, Viral/*antagonists & inhibitors[MESH] |RNA-Dependent RNA Polymerase/genetics[MESH] |SARS-CoV-2[MESH]Development of CRISPR as an Antiviral Strategy to Combat SARS-CoV-2 an(epmc).pdf DeepDyve Pubget Overpricing